LENZ Therapeutics Projected to Post Earnings on Wednesday

Analysts expect the biopharmaceutical company to report Q4 2025 results.

Mar. 11, 2026 at 6:19am

Got story updates? Submit your updates here. ›

LENZ Therapeutics (NASDAQ:LENZ) is expected to release its Q4 2025 financial results before the market opens on Wednesday, March 18, 2026. Analysts forecast the company will post earnings of ($0.91) per share and revenue of $3.0880 million for the quarter.

Why it matters

As a biopharmaceutical company focused on developing therapies to improve vision, LENZ Therapeutics' quarterly earnings report will provide insight into the progress and performance of its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials for the treatment of presbyopia.

The details

LENZ Therapeutics will host a conference call to discuss the Q4 2025 results on Wednesday, March 18, 2026 at 4:00 PM ET. The company's stock has seen significant volatility over the past year, trading between a 52-week low of $11.21 and a high of $50.40.

  • LENZ Therapeutics will release its Q4 2025 earnings before the market opens on Wednesday, March 18, 2026.
  • The company will host a conference call to discuss the results on Wednesday, March 18, 2026 at 4:00 PM ET.

The players

LENZ Therapeutics, Inc.

A biopharmaceutical company focused on developing and commercializing therapies to improve vision in the United States. The company's lead product candidates are LNZ100 and LNZ101, which are in Phase III clinical trials for the treatment of presbyopia.

Got photos? Submit your photos here. ›

The takeaway

Investors will be closely watching LENZ Therapeutics' Q4 2025 earnings report for updates on the progress and performance of the company's lead product candidates as it works to develop new treatments for vision-related conditions.